Table 3 Intravitreal Aflibercept Treatment and Outcomes Following Switch to Intravitreal Aflibercept
Patients (n = 125) | |
|---|---|
Delay between last injection of ranibizumab and first IVT-AFL, days | 61.2 (46.1) |
Reasons for switch to IVT-AFL, n (%) | |
Refractory | 122 (97.6%) |
AE/SAE | 3 (2.4%) |
Other | 0 (0%) |
Time between diagnosis of nAMD and first IVT-AFL, months | 7.4 (3.3) |
Duration of IVT-AFL treatment, months | 11.3 (3.1) |
Follow-up duration, months | 12.7 (2.0) |
Number of IVT-AFL injections | 7.5 (2.6) |
BCVA, ETDRS letters | |
Baseline (switch to IVT-AFL) | 66.2 (12.1) |
Month 12 | 67.7 (13.6) |
Change in BCVA score between baseline and 12 months | 1.5 (10.3) |
P value | 0.105 |
CRT, μm | |
Baseline (switch to IVT-AFL) | 331.2 (103.3) |
Month 12 | 286.2 (84.7) |
Change in CRT between baseline and 12 months | −45.0 (101.1) |
P value | < 0.001 |
Patients with SRF, n (%) | |
Baseline | 87 (70.7) |
Month 12 | 58 (48.3) |
Patients with IRF, n (%) | |
Baseline | 44 (35.8) |
Month 12 | 27 (22.5) |